Parkinson's disease and dementia

Research output: Contribution to journalArticle

Abstract

Parkinson's disease affects as many as 1 million Americans and with advanced age is complicated by dementia in a majority of cases. However, the recognition of cognitive impairment in Parkinson's disease is made complicated by the predominance of motor symptoms and a neuropsychiatric profile that differs from the more common dementia of the Alzheimer's type. Differentiating the decline in personal and social activities due to cognitive impairment rather than preexisting movement disorder is difficult. Several expert bodies have addressed the use of cholinesterase inhibitors for the dementia of Parkinson's disease, but the evidence base is far less substantial than that which exists for Alzheimer's disease. Although most patients with Parkinson's disease dementia should be offered a trial of anti-cholinesterase therapy, particularly those experiencing hallucinations, dramatic benefits are not common. Temporary symptomatic relief rather than disease modification is the most that can be expected. As a result, treatment should be presented as an option rather than an imperative.

Original languageEnglish (US)
Pages (from-to)19-23
Number of pages5
JournalPrimary Psychiatry
Volume16
Issue number4
StatePublished - Apr 2009

Fingerprint

Parkinson Disease
Dementia
Cholinesterase Inhibitors
Alzheimer Disease
Preexisting Condition Coverage
Hallucinations
Movement Disorders
Therapeutics
Cognitive Dysfunction

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Parkinson's disease and dementia. / Kennedy, Gary J.

In: Primary Psychiatry, Vol. 16, No. 4, 04.2009, p. 19-23.

Research output: Contribution to journalArticle

Kennedy, Gary J. / Parkinson's disease and dementia. In: Primary Psychiatry. 2009 ; Vol. 16, No. 4. pp. 19-23.
@article{4af8c709cb5440b5b739be956a8aee13,
title = "Parkinson's disease and dementia",
abstract = "Parkinson's disease affects as many as 1 million Americans and with advanced age is complicated by dementia in a majority of cases. However, the recognition of cognitive impairment in Parkinson's disease is made complicated by the predominance of motor symptoms and a neuropsychiatric profile that differs from the more common dementia of the Alzheimer's type. Differentiating the decline in personal and social activities due to cognitive impairment rather than preexisting movement disorder is difficult. Several expert bodies have addressed the use of cholinesterase inhibitors for the dementia of Parkinson's disease, but the evidence base is far less substantial than that which exists for Alzheimer's disease. Although most patients with Parkinson's disease dementia should be offered a trial of anti-cholinesterase therapy, particularly those experiencing hallucinations, dramatic benefits are not common. Temporary symptomatic relief rather than disease modification is the most that can be expected. As a result, treatment should be presented as an option rather than an imperative.",
author = "Kennedy, {Gary J.}",
year = "2009",
month = "4",
language = "English (US)",
volume = "16",
pages = "19--23",
journal = "Primary Psychiatry",
issn = "1082-6319",
publisher = "MBL Communications",
number = "4",

}

TY - JOUR

T1 - Parkinson's disease and dementia

AU - Kennedy, Gary J.

PY - 2009/4

Y1 - 2009/4

N2 - Parkinson's disease affects as many as 1 million Americans and with advanced age is complicated by dementia in a majority of cases. However, the recognition of cognitive impairment in Parkinson's disease is made complicated by the predominance of motor symptoms and a neuropsychiatric profile that differs from the more common dementia of the Alzheimer's type. Differentiating the decline in personal and social activities due to cognitive impairment rather than preexisting movement disorder is difficult. Several expert bodies have addressed the use of cholinesterase inhibitors for the dementia of Parkinson's disease, but the evidence base is far less substantial than that which exists for Alzheimer's disease. Although most patients with Parkinson's disease dementia should be offered a trial of anti-cholinesterase therapy, particularly those experiencing hallucinations, dramatic benefits are not common. Temporary symptomatic relief rather than disease modification is the most that can be expected. As a result, treatment should be presented as an option rather than an imperative.

AB - Parkinson's disease affects as many as 1 million Americans and with advanced age is complicated by dementia in a majority of cases. However, the recognition of cognitive impairment in Parkinson's disease is made complicated by the predominance of motor symptoms and a neuropsychiatric profile that differs from the more common dementia of the Alzheimer's type. Differentiating the decline in personal and social activities due to cognitive impairment rather than preexisting movement disorder is difficult. Several expert bodies have addressed the use of cholinesterase inhibitors for the dementia of Parkinson's disease, but the evidence base is far less substantial than that which exists for Alzheimer's disease. Although most patients with Parkinson's disease dementia should be offered a trial of anti-cholinesterase therapy, particularly those experiencing hallucinations, dramatic benefits are not common. Temporary symptomatic relief rather than disease modification is the most that can be expected. As a result, treatment should be presented as an option rather than an imperative.

UR - http://www.scopus.com/inward/record.url?scp=76749151394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76749151394&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 19

EP - 23

JO - Primary Psychiatry

JF - Primary Psychiatry

SN - 1082-6319

IS - 4

ER -